What do systematic reviews say?

Summary of findings ‐ nebulisers for delivering colistin: conventional systems vs AAD

The review found no eligible studies for this question.

• Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

NB‐UVB vs UVA1

• Phototherapy for atopic eczema 2021 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 46 participants
  Very low

Summary of findings ‐ nebulisers for delivering tobramycin: conventional systems vs VMT and AAD

The review found no eligible studies for this question.

• Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings ‐ nebulisers for delivering tobramycin: conventional systems vs AAD

The review found no eligible studies for this question.

• Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings ‐ nebulisers for delivering dornase alfa conventional system vs AAD

The review found no eligible studies for this question.

• Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings ‐ nebulisers for delivering tobramycin: conventional systems vs VMT

The review found no eligible studies for this question.

• Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings ‐ Pfaffia paniculata vs placebo

• Phytomedicines (medicines derived from plants) for sickle cell disease 2020 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 30 participants
  Very low

Summary of findings: insulin detemir vs insulin glargine

The review found no eligible studies for this question.

• (Ultra‐)long‐acting insulin analogues for people with type 1 diabetes mellitus 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings table ‐ Adjunctive therapies in addition to land‐based exercise therapy vs placebo adjunctive therapies

• Adjunctive therapies in addition to land‐based exercise therapy for osteoarthritis of the hip or knee 2022 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 82 participants
  Moderate

Summary of findings table (subcomparison 3): chemotherapy agent(s) plus control intervention vs control intervention

• Palliative chemotherapy and targeted therapies for esophageal and gastroesophageal junction cancer 2017 · Cochrane Headline outcomes only
  no estimate extracted
  450 participants
  Very low

Summary of findings table (subcomparison 4): targeted therapy agent plus control intervention vs control intervention

• Palliative chemotherapy and targeted therapies for esophageal and gastroesophageal junction cancer 2017 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 2054 participants
  Very low

Summary of findings table (subcomparison 5): chemotherapy or targeted therapy agent(s) plus control intervention vs control intervention

• Palliative chemotherapy and targeted therapies for esophageal and gastroesophageal junction cancer 2017 · Cochrane Headline outcomes only
  no estimate extracted
  5 studies · 1870 participants
  Very low

Inhaled corticosteroids vs placebo

• Inhaled corticosteroids versus placebo for stable chronic obstructive pulmonary disease 2023 · Cochrane Headline outcomes only
  no estimate extracted
  5 studies · 2507 participants
  Moderate

Summary of findings: levodopa vs other dopamine agonists

• Levodopa for the treatment of restless legs syndrome 2011 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 314 participants
  Moderate

Summary of findings ‐ nebulisers for delivering tobramycin: VMT and AAD tidal breathing mode (TBM) vs VMT and AAD target inhalation mode (TIM)

The review found no eligible studies for this question.

• Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings ‐ nebulisers for delivering other aerosolised medications: conventional systems vs AAD

The review found no eligible studies for this question.

• Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings ‐ nebulisers for delivering other aerosolised medications: conventional systems vs nebuliser

The review found no eligible studies for this question.

• Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: levodopa vs placebo

• Levodopa for the treatment of restless legs syndrome 2011 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 60 participants
  Moderate

Summary of findings table ‐ Psychosocial interventions intended primarily to reduce antipsychotic use vs (Optimised) usual care

• Psychosocial interventions for reducing antipsychotic medication in care home residents 2023 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 2 participants
  Moderate

naltrexone vs placebo

The review found no eligible studies for this question.

• Pharmacological interventions for pruritus in adult palliative care patients 2024 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found